| Trial ID: | L3197 |
| Source ID: | NCT01527539
|
| Associated Drug: |
Biphasic Insulin Aspart 30
|
| Title: |
Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: biphasic insulin aspart 30
|
| Outcome Measures: |
Primary: HbA1c | Secondary: Occurrence of adverse events|Occurence of hypoglycaemic episodes
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
25
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2001-11-23
|
| Completion Date: |
2004-10-12
|
| Results First Posted: |
|
| Last Update Posted: |
2017-02-24
|
| Locations: |
Novo Nordisk Investigational Site, Halifax, Nova Scotia, B3H 1V7, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, M5B 1W8, Canada|Novo Nordisk Investigational Site, Edmonton, T5H 3V9, Canada|Novo Nordisk Investigational Site, Windsor, N8W 3K2, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT01527539
|
